Results 11 to 20 of about 15,824 (192)
Pharmacokinetics of Aztreonam-Avibactam After Single- and Multiple-Dose Administration: A Phase 1, Open-Label Study in Healthy Chinese Participants and Ethnic Comparison with Non-Chinese Participants. [PDF]
Clin Pharmacol Drug DevABSTRACT Combined treatment with aztreonam (an established intravenous antibiotic) and avibactam (a β‐lactamase inhibitor) has the potential to address the unmet need for safe and effective agents to combat infections caused by Gram‐negative bacteria producing metallo β‐lactamases (MBLs).
Wang J +10 more
europepmc +2 more sources
Antibiotics, 2022 Metallo-beta-lactamases-producing (MBL) Enterobacterales is a growing problem worldwide. The optimization of antibiotic therapy is challenging. The pivotal available therapeutic options are either the combination of ceftazidime/avibactam and aztreonam or
Jean-François Timsit +2 more
doaj +1 more source
Microorganisms, 2020 Increasing carbapenem resistance rates worldwide underscored the urgent need of novel antimicrobials. Ceftazidime–avibactam and aztreonam–avibactam combinations are developed to combat carbapenem resistance, but biological and geographic variations must ...
Tsung-Ying Yang +10 more
doaj +1 more source
Recent Developments to Cope the Antibacterial Resistance via β-Lactamase Inhibition
Molecules, 2022 Antibacterial resistance towards the β-lactam (BL) drugs is now ubiquitous, and there is a major global health concern associated with the emergence of new β-lactamases (BLAs) as the primary cause of resistance.
Zafar Iqbal +11 more
doaj +1 more source
Successful Treatment of Acute Prostatitis Caused by Multidrug-Resistant Escherichia coli With Tigecycline Monotherapy [PDF]
, 2020 We present a successful treatment, with tigecycline monotherapy, of acute prostatitis caused by multidrug-resistant Escherichia coli harboring an NDM-1 carbapemenase along with a CMY-2 cephalosporinase and a TEM ...
Babouee Flury, Baharak +7 more
core +2 more sources
Cefdinir and β-Lactamase Inhibitor Independent Efficacy Against Mycobacterium tuberculosis
Frontiers in Pharmacology, 2021 Background: There is renewed interest in repurposing β-lactam antibiotics for treatment of tuberculosis (TB). We investigated efficacy of cefdinir, that withstand the β-lactamase enzyme present in many bacteria, against drug-susceptible and multi-drug ...
Shashikant Srivastava +10 more
doaj +1 more source
European intensive care physicians’ experience of infections due to antibiotic-resistant bacteria [PDF]
, 2020 Background Antimicrobial resistance (AMR) compromises the treatment of patients with serious infections in intensive care units (ICUs), and intensive care physicians are increasingly facing patients with bacterial infections with limited or no adequate ...
De Waele, Jan +9 more
core +2 more sources
Antibiotics, 2022 The role of β-lactamases in reduced susceptibility or resistance to cefiderocol has been supported by recent reports. The purpose of this study was to investigate the in vitro impact of clinically available β-lactamase inhibitors on cefiderocol activity ...
Gabriele Bianco +7 more
doaj +1 more source
Revista Española de Quimioterapia, 2022 The increase in nosocomial infections by beta-lactamase producing Gram-negative bacilli constitutes a therapeutic challenge. The combination of ceftazidime-avibactam offers a very interesting therapeutic option for nosocomial pneumonia caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae, multidrug-resistant Pseudomonas aeruginosa,
openaire +2 more sources
Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia [PDF]
, 2020 BACKGROUND: Cefiderocol is a novel siderophore cephalosporin, developed for activity against MDR Gram-negative bacilli (MDR-GNB). OBJECTIVES: To assess the in vitro antibacterial activity of cefiderocol against a collection of MDR-GNB clinical ...
Conejo, Mª del Carmen +4 more
core +1 more source